• English
  • Sign In
  • Contact Us
×
Catalog Products » Recombinant Proteins » Cytokines » VEGF R2/KDR Fc Chimera, Human

VEGF R2/KDR, Human

Synonyms CD309; Flk-1; KDR
Description Vascular endothelial growth factor receptor 2 (VEGF R2) , also known as Kinase insert domain receptor (KDR) and Fetal Liver Kinase 1 (Flk-1), is a type III receptor tyrosine kinase which plays a critical role in angiogenesis. VEGFR-1 and VEGFR-2 are closely related receptor tyrosine kinases and have both common and specific ligands. VEGFR-1 is a kinase-impaired RTK whereas VEGFR-2 is a highly active kinase. Vascular endothelial growth factors (VEGFs) are crucial regulators of vascular development during embryogenesis (vasculogenesis) as well as blood-vessel formation (angiogenesis) in the adult. In mammals, five VEGF ligands, which occur in several different splice variants and processed forms, have been identified so far. These ligands bind in an overlapping pattern to three receptor tyrosine kinases (RTKs), known as VEGF receptor-1, -2 and -3 (VEGFR1-3), as well as to co-receptors (here defined as VEGF-binding molecules that lack established VEGF-induced catalytic function), such as heparin sulphate proteoglycans (HSPGs) and neuropilins.
Recombinant Human VEGF R2/KDR produced in CHO cells is a polypeptide chain containing 978 amino acids. rhVEGFR2/KDR has a molecular mass of 150 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.
Accession No P35968
Source CHO
Biological Activity Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC (human umbilical vein endothelial cells).The ED50 for this effect is < 30 ng/mL in the presence of 5 ng/mL rhVEGF165 (Catalog: Z02689-10).
Sequence
ASVGLPSVSL DLPRLSIQKD ILTIKANTTL QITCRGQRDL
DWLWPNNQSG SEQRVEVTEC SDGLFCKTLT IPKVIGNDTG
AYKCFYRETD LASVIYVYVQ DYRSPFIASV SDQHGVVYIT ENKNKTVVIP
CLGSISNLNV SLCARYPEKR FVPDGNRISW DSKKGFTIPS
YMISYAGMVF CEAKINDESY QSIMYIVVVV GYRIYDVVLS PSHGIELSVG
EKLVLNCTAR TELNVGIDFN WEYPSSKHQH KKLVNRDLKT QSGSEMKKFL
STLTIDGVTR SDQGLYTCAA SSGLMTKKNS TFVRVHEKPF VAFGSGMESL
VEATVGERVR IPAKYLGYPP PEIKWYKNGI PLESNHTIKA GHVLTIMEVS
ERDTGNYTVI LTNPISKEKQ SHVVSLVVYV PPQIGEKSLI
SPVDSYQYGT TQTLTCTVYA IPPPHHIHWY WQLEEECANE PSQAVSVTNP
YPCEEWRSVE DFQGGNKIEV NKNQFALIEG KNKTVSTLVI QAANVSALYK
CEAVNKVGRG ERVISFHVTR GPEITLQPDM QPTEQESVSL WCTADRSTFE
NLTWYKLGPQ PLPIHVGELP TPVCKNLDTL WKLNATMFSN STNDILIMEL
KNASLQDQGD YVCLAQDRKT KKRHCVVRQL TVLERVAPTI
TGNLENQTTS IGESIEVSCT ASGNPPPQIM WFKDNETLVE DSGIVLKDGN
RNLTIRRVRK EDEGLYTCQA CSVLGCAKVE AFFIIEGAQE KTNLEIEGRM
DDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE
DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY
KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK

Measured Molecular Weight 150 kDa, observed by reducing SDS-PAGE.
Purity > 98% as analyzed by SDS-PAGE&HPLC.
Formulation Lyophilized after extensive dialysis against PBS.
Reconstitution Reconstituted in ddH2O or PBS at 100 μg/ml.
Endotoxin Level < 0.2 EU/μg, determined by LAL method.
Storage Lyophilized recombinant Human VEGF R2/KDR remains stable up to 6 months at lower than -70°C from date of receipt. Upon reconstitution, Human VEGF R2/KDR should be stable up to 1 week at 4°C or up to 3 months at -20°C.For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.
Note For research use only

  • VEGF R2/KDR, Human
  • VEGF R2/KDR, Human

    Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC (human umbilical vein endothelial cells).The ED₅₀ for this effect is < 30 ng/mL in the presence of 5 ng/mL rhVEGF165 (Catalog: Z02689-10).




Notice there is no results found, you can visit "Citations Database" for other results.







For more documents, please visit "Technical Support".

Cat. No. Z03366
Size
Price
50 ug $149.00